Single-dose base editing corrects PKD1 mutation and extends survival in ADPKD preclinical models

Mayo Clinic researchers have developed a promising gene-editing therapy that directly corrects a genetic mutation responsible for autosomal dominant polycystic kidney disease (ADPKD), the most common inherited kidney disorder.

Continue Reading

News Source: medicalxpress.com